Illumina, Inc. $ILMN Stock: Sumitomo Mitsui DS Asset Management Company Ltd Raises Position

Sumitomo Mitsui DS Asset Management Company Ltd grew its position in Illumina, Inc. (NASDAQ:ILMN) by 36.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 20,671 shares of the life sciences company’s stock after acquiring an additional 5,467 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Illumina were worth $5,657,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Illumina during the 2nd quarter worth about $3,374,423,000. WCM Investment Management LLC raised its position in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after acquiring an additional 1,851,848 shares in the last quarter. Primecap Management Co. CA bought a new position in Illumina during the second quarter valued at approximately $617,981,000. Janus Henderson Group PLC lifted its stake in Illumina by 1.4% in the first quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company’s stock valued at $258,924,000 after acquiring an additional 29,094 shares during the last quarter. Finally, Southpoint Capital Advisors LP lifted its stake in Illumina by 20.0% in the first quarter. Southpoint Capital Advisors LP now owns 2,100,000 shares of the life sciences company’s stock valued at $258,846,000 after acquiring an additional 349,536 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Illumina news, Director Keith Meister sold 457,858 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 2,061,850 shares of company stock worth $436,479,102 in the last three months. 2.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ILMN. Stifel Nicolaus raised their price target on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a report on Friday, July 31st. Barclays lifted their price objective on shares of Illumina from $160.00 to $200.00 and gave the company an “underweight” rating in a research note on Wednesday, October 7th. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a report on Sunday, October 11th. Royal Bank Of Canada increased their target price on shares of Illumina from $230.00 to $310.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Finally, Deutsche Bank Aktiengesellschaft lowered Illumina to a “hold” rating in a report on Wednesday, August 5th. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Illumina presently has an average rating of “Hold” and an average price target of $231.88.

Illumina Price Performance

NASDAQ:ILMN opened at $282.86 on Thursday. The company has a 50-day moving average of $239.24 and a 200-day moving average of $189.54. The company has a market capitalization of $42.71 billion, a price-to-earnings ratio of 52.77, a PEG ratio of 3.79 and a beta of 1.41. Illumina, Inc. has a 52 week low of $94.00 and a 52 week high of $309.35. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm’s revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.